Carole Huntsman sold $598k of MDGL
Chief Commercial Officer at MADRIGAL PHARMACEUTICALS, INC.. 1,834 shares at an average of $325.98, traded Mar 3, 2025, filed Mar 5, 2025.
Score components
- +15RoleOfficer
- +19Trade size$598k at market
- +5Share of holdings soldSold 18% of holdings
- +15Cluster6 insiders selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001628280-25-010492, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Mar 3, 2025 | SOpen-market sale Common Stock10b5-1 | -71 | $313.08 | $22k | 10,367 | Mar 5, 2025 |
| Mar 3, 2025 | SOpen-market sale Common Stock10b5-1 | -200 | $314.74 | $63k | 10,167 | Mar 5, 2025 |
| Mar 3, 2025 | SOpen-market sale Common Stock10b5-1 | -300 | $320.21 | $96k | 9,867 | Mar 5, 2025 |
| Mar 3, 2025 | SOpen-market sale Common Stock10b5-1 | -200 | $323.65 | $65k | 9,667 | Mar 5, 2025 |
| Mar 3, 2025 | SOpen-market sale Common Stock10b5-1 | -200 | $324.59 | $65k | 9,467 | Mar 5, 2025 |
| Mar 3, 2025 | SOpen-market sale Common Stock10b5-1 | -100 | $326.34 | $33k | 9,367 | Mar 5, 2025 |
| Mar 3, 2025 | SOpen-market sale Common Stock10b5-1 | -100 | $327.49 | $33k | 9,267 | Mar 5, 2025 |
| Mar 3, 2025 | SOpen-market sale Common Stock10b5-1 | -100 | $329.64 | $33k | 9,167 | Mar 5, 2025 |
| Mar 3, 2025 | SOpen-market sale Common Stock10b5-1 | -563 | $335.00 | $189k | 8,604 | Mar 5, 2025 |
Related signals
Other insiders at MADRIGAL PHARMACEUTICALS, INC. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 30Weak | MADRIGAL PHARMACEUTICALS, INC. | William John Sibold President and CEO | $6.2M 11,583 shares | -6% | |
| 40Moderate | MADRIGAL PHARMACEUTICALS, INC. | Fred B Craves director | $5.1M 15,470 shares | -4% | |
| 26Weak | MADRIGAL PHARMACEUTICALS, INC. | Mardi Dier SVP and CFO | $83k 258 shares | -2% | |
| 42Moderate | MADRIGAL PHARMACEUTICALS, INC. | Mardi Dier SVP and CFO | $637k 1,961 shares | -22% | |
| 21Weak | MADRIGAL PHARMACEUTICALS, INC. | Shannon T Kelley General Counsel | $139k 415 shares | -5% | |
| 60Notable | MADRIGAL PHARMACEUTICALS, INC. | Kenneth Bate director | $7.1M 20,000 shares | -91% | |
| 60Notable | MADRIGAL PHARMACEUTICALS, INC. | James M Daly director | $5.4M 15,470 shares | -89% | |
| 33Weak | MADRIGAL PHARMACEUTICALS, INC. | Carole Huntsman Chief Commercial Officer | $116k 347 shares | -3% | |
| 31Weak | MADRIGAL PHARMACEUTICALS, INC. | Shannon T Kelley General Counsel | $76k 277 shares | -3% | |
| 53Moderate | MADRIGAL PHARMACEUTICALS, INC. | Fred B Craves director | $1.1M 3,600 shares | -25% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.